Industry Pharmaceutical Headquarters Bengaluru Founded 1990 | Number of employees approximately 4600 Revenue 566 million USD (2014) | |
 | ||
Type MNC (several JVs, and subsidiaries) Key people Arun Kumar (Founder and Group CEO),
K R Ravishankar, Deepak Vaidya (Chairman) Products Hard gelatin, solid dosage,Tablets,Formulations Parent Strides Arcolab Limited Stock price STAR (NSE) ₹ 1,111.00 -18.60 (-1.65%)29 Mar, 3:30 PM IST - Disclaimer CEO Shashank Sinha (Mar 2016–) Motto Leadership through Partnering Subsidiaries Shasun Chemicals & Drugs, Co-pharma Limited | ||
Strides Arcolab is an Indian pharmaceutical company, headquartered at Bangalore in southern India. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. Its softgel manufacturing capability consists of an annual capacity of 50,000 machine hours or about three billion softgel capsules. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. In the United States and Canadian markets, the company partners with generic companies to supply retail and hospital generics in injectable products and softgels. In European markets, it has long-term relationships for the development of projects and supply agreements with the European companies. In Australia and New Zealand, the company is engaged in manufacturing and supply of soft gels and value-added manufacturing. The company has development and supply agreements with South African companies. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India.
Contents
Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies.
Arun Kumar is the founder and Group CEO, and has been on the Board as Managing Director since its inception. Abhaya Kumar is an executive director. Deepak Vaidya was appointed to the board in January, 1998, and was made Chairman of the Board.
Indian plants
In India the company operates eight pharmaceutical plants:
On December 5, 2013, the company announced that it had completed the sale of its Agila Specialties Division to Mylan Inc., for a total sum of up to US$1.75 billion.
Non-Indian plants
Global Disease Initiative
Strides is in the international market for quality generics to fight HIV/ AIDS, TB and malaria. The company works with the Clinton Foundation to make available a range of lower cost anti-retroviral drugs for the treatment of HIV/AIDS as part of the Clinton Foundation's HIV/AIDS initiative. The company is also on the list of World Health Organization pre-qualified suppliers to supply generic fixed dose combination of anti-HIV drugs. It is an approved supplier to the World Bank, the African Development Bank, PEPFAR President's Emergency Plan For AIDS Relief and UNICEF.